Liver-allocation policies for patients affected by HCC in Europe

Current Transplantation Reports

Volumn 3, Issue 4, 2016, Pages 313-318

  De Carlis, Luciano ^a,b   Di Sandro, Stefano ^b,c   Centonze, Leonardo ^b   Lauterio, Andrea ^b   Buscemi, Vincenzo ^b,c   De Carlis, Riccardo ^b,c   Ferla, Fabio ^b   Sguinzi, Raffaella ^b   Okolicsanyi, Stefano ^a   Belli, Luca ^b   Strazzabosco, Mario ^a,d  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

allocation policy; Europe; Hepatocellular Carcinoma; liver transplantation

Indexed keywords

EID: 85056205642     PISSN: None     EISSN: 21963029     Source Type: Journal    
DOI: 10.1007/s40472-016-0117-6     Document Type: Article

References (27)

1. Ringe B, Pichlmayr R, Tusch G. Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg. 1991;15(2):270–85. DOI: 10.1007/BF01659064
2. Ryder SD. Guidelines for the diagnosis and treatment of hepato- cellular carcinoma (HCC) in adults. Gut. 2003;52 Suppl 3: p. iii1-iii8.
3. Mazzaferro V et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–9. DOI: 10.1056/NEJM199603143341104
4. Adam R et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol. 2012;57(3):675–88. doi:10.1016/j.jhep.2012.04.015. DOI: 10.1016/j.jhep.2012.04.015
5. Ioannou GN, Perkins JD, Carithers Jr RL. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology. 2008;134(5):1342–51. DOI: 10.1053/j.gastro.2008.02.013
6. Toso C, Majno P, Berney T, Morel P, Mentha G, Combescure C. Validation of a dropout assessment model of candidates with/without hepatocellular carcinoma on a common liver transplant waiting list. Transplant Int. 2014;27:686–95. DOI: 10.1111/tri.12323
7. Merani S, Majno P, Kneteman NM, et al. The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J Hepatol. 2011;55:814–9. DOI: 10.1016/j.jhep.2010.12.040
8. Toso C, Mentha G, Majno P. Liver transplantation for hepatocellular carcinoma: Five steps to prevent recurrence. Am J Transplant. 2011;11:2031–5. DOI: 10.1111/j.1600-6143.2011.03689.x
9. Toso C, Mazzaferro V, Bruix J, et al. Toward a better liver graft allocation that accounts for candidates with and without hepatocellular carcinoma. Am J Transplant. 2014;14(10):2221–7. DOI: 10.1111/ajt.12923
10. Merion RM, Schaubel DE, Dykstra DM, Freeman RB, Port FK, Wolfe RA. The survival benefit of liver transplantation. Am J Transplant. 2005;5:307–13. DOI: 10.1111/j.1600-6143.2004.00703.x
11. Schaubel DE, Sima CS, Goodrich NP, Feng S, Merion RM. The survival benefit of deceased donor liver transplantation as a function of candidate disease severity and donor quality. Am J Transplant. 2008;8:419–25. DOI: 10.1111/j.1600-6143.2007.02086.x
12. Cillo U, Vitale A, Volk ML, et al. The survival benefit of liver transplantation in hepatocellular carcinoma patients. Dig Liver Dis. 2010;42:642–9. DOI: 10.1016/j.dld.2010.02.010
13. Ravaioli M, Grazi GL, Ercolani G, et al. Liver allocation for hepatocellular carcinoma: A European center policy in the pre-MELD era. Transplantation. 2006;81:525–30. DOI: 10.1097/01.tp.0000198741.39637.44
14. Ravaioli M, Grazi GL, Ballardinin G, et al. Liver transplantation with the Meld system: a prospective study from a single European center. Am J Transplant. 2006;6:1572–7. DOI: 10.1111/j.1600-6143.2006.01354.x
15. Vitale A, Volk ML, De Feo TM, et al. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list. J Hepatol. 2014;60:290–7. This article provides the first model in which HCC and non-HCC patients are equally prioritized according to transplant benefit. DOI: 10.1016/j.jhep.2013.10.010
16. Eurotransplant manual. Chap 5. Available at www.eurotransplant.org
17. Ramos RE, Ortiz de Urbina J, Santoyo Santoyo J, et al. Degree of uniformity in the treatment of hepatocellular carcinoma in the Spanish teams of liver transplantation [Spanish]. Med Clin (Barc). 2013;141(9):406–10. DOI: 10.1016/j.medcli.2013.03.009
18. V Consensus Meeting of the Spanish Society for Liver Transplant on high-risk recipients, immunosupression scenarios and management of hepatocarcinoma on the transplant waiting list. Cir Esp. 2015;93(10):619-37. doi: 10.1016/j.ciresp.2015.04.007 DOI: 10.1016/j.ciresp.2015.04.007
19. Francoz C et al. Model for end-stage liver disease exceptions in the context of the french model for end-stage liver disease score-based liver allocation system. Liver Transpl. 2011;17:1137–51. DOI: 10.1002/lt.22363
20. Barber KM, Pioli S, Blackwell JE, et al. Development of a UK score for patients with end-stage liver disease. Hepatology. 2007;46:510A.
21. Menon KV, Hakeem AR, Heaton ND. Review article: liver transplantation for hepatocellular carcinoma - a critical appraisal of the current worldwide listing criteria. Aliment Pharmacol Ther. 2014;40(8):893–902. DOI: 10.1111/apt.12922
22. Fosby B et al. Liver transplantation in the nordic countries - an intention to treat and post-transplant analysis from the nordic liver transplant registry 1982-2013. Scand J Gastroenterol. 2015;50(6):797–808. doi:10.3109/00365521.2015.1036359. DOI: 10.3109/00365521.2015.1036359
23. Shukla A et al. Liver transplantation: east versus west. J Clin Exp Hepatol. 2013;3(3):243–53. doi:10.1016/j.jceh.2013.08.004. DOI: 10.1016/j.jceh.2013.08.004
24. Cillo U, Burra P, Mazzaferro V, et al. A multistep, consensus-based approach to organ allocation in liver transplantation: toward a “blended principle model”. Am J Transplant. 2015;15:2552–61. DOI: 10.1111/ajt.13408
25. Mazzaferro V. Squaring the circle of selection and allocation in liver transplantation for HCC: an adaptive approach. Hepatology. 2016;63(5):1707–17. This is a new perspective of patients’ priority for liver tranplantation due to HCC. This model is able to contemplate together tumor size and number, tumor response to the locoregional treatments, and feasibility of pre-transplant treatments. DOI: 10.1002/hep.28420
26. De Giorgio M, Vezzoli S, Cohen E, Armellini E, Lucà MG, Verga G, et al. Prediction of progression-free survival in patients presenting with hepatocellular carcinoma within the Milan criteria. Liver Transpl. 2010;16(4):503–12.
27. De Carlis L, Di Sandro S, Giacomoni A, Slim A, Lauterio A, Mangoni I, et al. Beyond the Milan criteria: what risks for patients with hepatocellular carcinoma progression before liver transplantation? J Clin Gastroenterol. 2012;46(1):78–86. DOI: 10.1097/MCG.0b013e31822b36f6